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Abstract
Fragile X syndrome is a genetic condition resulting from FMR1 gene mutation that leads to intellectual disability,
autism-like symptoms, and sensory hypersensitivity. Arbaclofen, a GABA-B agonist, has shown efficacy in some
individuals with FXS but has become unavailable after unsuccessful clinical trials, prompting interest in publicly
available, racemic baclofen. The present study investigated whether racemic baclofen can remediate abnormalities of
neural circuit function, sensory processing, and behavior in Fmr1 knockout mice, a rodent model of fragile X syndrome.
Fmr1 knockout mice showed increased baseline and auditory-evoked high-frequency gamma (30–80 Hz) power
relative to C57BL/6 controls, as measured by electroencephalography. These deficits were accompanied by de-
creased T maze spontaneous alternation, decreased social interactions, and increased open field center time,
suggestive of diminished working memory, sociability, and anxiety-like behavior, respectively. Abnormal auditory-
evoked gamma oscillations, working memory, and anxiety-related behavior were normalized by treatment with
baclofen, but impaired sociability was not. Improvements in working memory were evident predominantly in mice
whose auditory-evoked gamma oscillations were dampened by baclofen. These findings suggest that racemic
baclofen may be useful for targeting sensory and cognitive disturbances in fragile X syndrome.
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Introduction
Fragile X syndrome (FXS) is a debilitating neurodevel-
opmental disorder that results from mutation of the FMR1
gene (Verkerk et al. 1991) and loss of fragile X mental
retardation protein (FMRP). It affects 1 in 4000 males
and 1 in 8000 females (Turner et al. 1996) and is charac-
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Significance Statement
Baclofen stimulates the inhibitory GABA-B receptor and is the publicly available version of arbaclofen, a
candidate drug for fragile X syndrome that showed initial promise in clinical trials but did not succeed overall
and is now unavailable. Using the Fmr1 knockout mouse model of fragile X syndrome, we show that
baclofen may have potential for targeting abnormal sensory sensitivity (in the form of increased auditory-
evoked high-frequency neural oscillations) and cognitive deficits (particularly spatial working memory) in
fragile X syndrome. This work also highlights the possible usefulness of electroencephalography, which
measures neural oscillations, for predicting treatment responsiveness in select fragile X symptom domains.
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terized by cognitive deficits, hyperactivity, attention prob-
lems, social communication deficits, and increased
anxiety (Bailey et al. 2008). Approximately 40% of individ-
uals with FXS display symptoms of autism spectrum dis-
order (ASD; Bailey et al. 2008). Treatment options for FXS
are currently limited and have historically focused on
symptoms such as anxiety (Bailey et al. 2012). More
recently, evidence-based FXS pharmacotherapies (Healy
et al. 2011; Lozano et al. 2014) have emerged. Some such
therapies have targeted the -aminobutyric acid (GABA)
neurotransmitter signaling pathway, based on evidence of
GABAergic deficits in Fmr1 knockout (KO) mice (Gantois
et al. 2006; Adusei et al. 2010; Paluszkiewicz et al. 2011),
a rodent model with strong construct validity for FXS.
The GABA-B agonist arbaclofen (STX209) has shown
promise preclinically, rescuing behavioral abnormalities in
Fmr1 KOmice (Henderson et al. 2012; Qin et al. 2015) and
mouse models of ASD (Silverman et al. 2015). Studies on
the effects of arbaclofen in individual with FXS have
shown mixed results (Lozano et al. 2014). In adults and
children with FXS, arbaclofen did not improve overall
symptom severity (Berry-Kravis et al. 2012). However,
improvement in select symptom domains was seen in
some individuals, consistent with anecdotal evidence of
efficacy provided by families of individuals with FXS (Lo-
zano et al. 2014). In the face of these results, arbaclofen
trials in FXS were ceased in May 2015, and the drug was
made unavailable for clinical research.
The overall failure of arbaclofen in human FXS trials may
have occurred because arbaclofen is beneficial for only a
subset of individuals or is effective for only a limited
subset of symptoms. Furthermore, although arbaclofen is
currently unavailable for research or treatment, racemic
baclofen is available and may be used off-label for FXS.
As a result, it is critical to establish the usefulness of
racemic baclofen for treating key FXS symptom domains
and behaviors.
Sensory abnormalities are key symptoms of FXS and
ASD (Sinclair et al. 2016) that may differentiate individual
responses to baclofen. Sensory abnormalities can be ob-
jectively assessed using electroencephalography (EEG) in
both humans with FXS and Fmr1 KO mice. Humans with
FXS show evidence of auditory hypersensitivity, disrupted
preattentive stimulus recognition, and altered novelty de-
tection by EEG (St Clair et al. 1987; Castrén et al. 2003;
Van der Molen et al. 2012a, b; Ethridge et al. 2016), as do
Fmr1 KO mice (Chen and Toth, 2001; Frankland et al.
2004; Gibson et al. 2008; Lovelace et al. 2016). Because
abnormalities of sensory processing are likely to contrib-
ute to sensory hypersensitivity and other deficits in FXS,
they are an important potential target for baclofen treat-
ment.
Therefore, we had three primary aims. First, we set out
to determine the extent of sensory processing abnormal-
ities in Fmr1 KO mice, particularly at the level of in vivo
neural oscillations. Although EEG has been used previ-
ously in Fmr1 KO mice (Gonçalves et al. 2013; Radwan
et al. 2016), to our knowledge auditory-evoked oscilla-
tions have not been investigated. Second, we explored
whether EEG oscillation abnormalities and behavioral def-
icits in Fmr1 KO mice could be rescued by acute racemic
baclofen treatment. Fmr1 KO mice show abnormal loco-
motor activity, anxiety-like behavior, reduced social inter-
actions, and impaired working memory (Bakker et al.
1994; Kramvis et al. 2013; Hébert et al. 2014; Oddi et al.
2015), but the amenability of these deficits to racemic
baclofen treatment is unclear (Pacey et al. 2009). Finally,
we investigated whether rescue of specific EEG oscilla-
tion abnormalities at an individual level was associated
with improvement in behavior or cognition, as a proof of
concept for the possible future use of EEG to predict
treatment responsiveness in individuals with FXS.
Materials and Methods
Study design
This study compared inbred adult Fmr1 KO mice to
wild-type (WT) controls using a within-subject design,
testing the hypothesis that sensory hypersensitivity in
Fmr1 KO mice would be reflected in abnormal stimulus-
evoked neural activity and would relate to behavioral
deficits. Neural oscillations (at baseline and in response to
auditory stimulus), open-field behavior, social interac-
tions, spatial working memory, and spatial episodic mem-
ory were quantified sequentially in the same mice. Each
test was conducted on four separate days. Vehicle was
administered on test day 1, then 1 mg/kg baclofen on test
day 2, 2.5 mg/kg baclofen on test day 3 and 5 mg/kg
baclofen on test day 4, with 48 h washout between test
days. Based on previous experience of the sample size
required to reveal biologically relevant differences in EEG
and behavior (Gandal et al. 2012a, b; Billingslea et al.
2014; Tatard-Leitman et al. 2015), 15–23 mice per geno-
type and sex were used.
Animals and drug preparation
Homozygous female Fmr1 KO mice and hemizygous
male Fmr1 KO mice on a C57BL/6 background (strain
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name B6.129P2-Fmr1tm1Cgr/J, stock no. 003025; RRID:
MGI:4950026; Bakker et al. 1994), along with WT
C57BL/6 controls, were received from The Jackson Lab-
oratory at 28 d of age. Littermates did not serve as WT
controls, since the required breeding strategy for homozy-
gous female Fmr1 KO mice does not generate WT mice.
Animals were group-housed in standard cages (Allentown
Inc.) with food and water ad libitum, in a room maintained
on a 12 h light-dark cycle. Mice were habituated to the
colony environment for 4 weeks before electrode implan-
tation and underwent surgery at postnatal day 56. Ani-
mals were singly housed for the remainder of the study to
prevent postoperative complications. All protocols for an-
imal care and use were undertaken in accordance with
University Laboratory Animal Resources and NIH guide-
lines and were approved by the Institutional Animal Care
and Use Committee (University of Pennsylvania protocol
#803572). Racemic baclofen (cat. #5399; Sigma-Aldrich)
was dissolved in 0.9% saline immediately before use and
administered intraperitoneally at 1, 2.5, or 5 mg/kg in
100 l injection volume. Testing was conducted 5 min
after injection.
Electroencephalography
Animals were anaesthetized with isoflurane and im-
planted unilaterally with a tripolar electrode assembly. The
recording electrode was placed 1.8 mm posterior, 2.65
mm right lateral, and 2.75 mm deep relative to Bregma to
detect changes in the electrical field emanating from the
hippocampus and cortex. Reference and ground elec-
trodes were placed transversely onto the surface of the
ipsilateral neocortex, 0.8 mm deep (Featherstone et al.
2015). Electrodes were secured to the skull with ethyl
cyanoacrylate and dental cement. Mice were allowed a 10
d period of recovery before testing. Neural oscillations
were recorded within a Faraday cage using a high-
impedance differential AC amplifier (model #1800, A-M
Systems) and Spike 2 software (Cambridge Electronic
Design). Baseline oscillations were recorded in the first
minute of the session, 5 min after IP injection. Thereafter,
120 broadband white-noise stimuli (10 ms duration, 85 dB
with an 8 s interstimulus interval) were administered. Raw
EEG was filtered between 1 and 500 Hz, and individual
sweeps were rejected for movement artifact based on a
criterion of 2 root mean squared amplitude per mouse.
For event-related potentials (ERPs), the P20 peak was
defined as the largest positive voltage deflection between
15 and 30 ms and the N40 peak as the largest negative
voltage deflection between 30 and 100 ms. Baseline
power was derived by fast Fourier transformation (FFT)
using the FFT function native to Spike2. Baseline absolute
gamma power was quantified as the average gamma
power (30–80 Hz) across the 60 s prestimulus period.
Baseline relative gamma power was expressed as the
proportion of gamma power (30–80 Hz) relative to total
power (0–120 Hz). Event-related power from 0 to 200 ms
after stimulus was baseline-corrected and derived using
time-frequency decomposition methods native to the
EEGLAB toolbox (Delorme and Makeig, 2004; RRID:
SCR_007292) within Matlab (Mathworks; RRID: SCR_001622)
as previously described (Billingslea et al. 2014; Tatard-Leitman
et al. 2015).
Behavioral tests
Behavioral testing was performed with Fmr1 KO and
WT mice at 6–10 weeks of age. Testing took place during
the light phase. Each test was repeated on four separate
sessions for administration of vehicle or 1, 2.5, or 5 mg/kg
baclofen, with a 48 h washout between sessions. There
was a break of 4–5 days between each behavioral test.
The chronological order of tests was open field, continu-
ous T-maze, three-chamber social interaction, and mod-
ified radial water maze.
For the open-field test, mice acclimated in the testing
room for 15 min before recording. Five minutes after IP
injection with saline or baclofen, mice were placed in a
clear Perspex open-field recording chamber (40  40 cm)
divided into a 16  16 photobeam grid (Photobeam Ac-
tivity System, San Diego Instruments). Locomotor activity
(the number of photobeam breaks in 10 min), time spent
in the center of the chamber (central area, 15  15 cm),
and time spent in the periphery (peripheral area, 25 cm
zone flanking chamber walls) were the measures of inter-
est, quantified using Photobeam Activity System software
(San Diego Instruments). Two mice at 5 mg/kg baclofen
(one female WT and one female KO) were omitted be-
cause of technical problems recording the test.
The apparatus used for assessing social interaction
consisted of two interaction chambers (19 cm wide, 26
cm deep, and 22 cm tall), each containing a wire mesh
cylinder (8 cm in diameter, 12 cm tall) as previously de-
scribed (Sankoorikal et al. 2006; Ehrlichman et al. 2009).
The interaction chambers were separated by a central
chamber (13 cm wide, 26 cm deep, and 22 cm tall). The
walls between chambers had an opening 11 cm wide. The
testing room was maintained under dim light. At the start
of the test the mesh cylinders were empty, and test mice
were placed in the apparatus to habituate for 10 min. Mice
were then injected with saline or baclofen and returned to
their home cages for 5 min. For the interaction test, a
female A/J stimulus mouse was placed in one mesh
cylinder and an inanimate object (tennis ball) was placed
in the other. Test mice were then reintroduced into the
testing apparatus and the experimenter left the room.
Social interaction was quantified as the number of sniffing
bouts at the mesh cylinder containing the stimulus mouse
(social) versus the inanimate object (nonsocial). The num-
ber of social and nonsocial interactions was scored man-
ually and expressed as a percentage of the total number
of interactions. Seven mice (three female WT and four
male WT) were assessed in the vehicle condition but not
included in further analyses because of technical difficul-
ties with recording during one baclofen test session.
Working memory was assessed using the spontaneous
alternation T-maze. Mice were acclimated in white light in
a room adjacent to the testing room for 15 min before
recording. Five minutes after injection of saline or
baclofen, mice were placed at the end of the central arm
of an opaque plastic T-maze (arm dimensions 30 cm long,
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10 cm wide, and 12 cm tall), which contained 1 cm of
fresh bedding. Navigation of the mouse in the maze was
recorded for 5 min with a Sony NightShot digital camera.
Arm entries were scored manually, with an entry recorded
if the mouse progressed more than halfway into the arm
and a correct alternation recorded if the entry occurred in
the most novel (least recently visited) arm. The number of
correct entries, as a percentage of total entries during the
5 min test, was scored manually. One male WT mouse
was assessed in the vehicle but did not complete the test
at 1 mg/kg baclofen and was excluded. Testing took
place in a dimly lit room.
Finally, episodic memory was assessed on a modified
radial water maze task. The apparatus consisted of four
transparent plastic arms (arm dimensions 30 cm long, 10
cm wide, and 24 cm tall), with a 20 cm square central zone
contained in a room under white light with distal visual
cues (wall posters). The maze was filled to a depth of 1 cm
with an opaque mixture of room temperature water and
white tempura paint. This depth of water was sufficient to
motivate the mice to find the platform and also to hide the
platform. At the end of one arm, a white platform was
placed level with the water surface. Mice were trained for
three consecutive days, and on each day were given five
trials (training trials) to locate the platform. Mice were
gently shepherded to the platform if they were unable to
locate the platform after 60 s. Mice were dried and al-
lowed to recuperate for 15 min on a heated home cage-
like enclosure between trials. On each sequential trial, the
arm in which the mouse started the test was varied. Test
days commenced 48 h after the last training day. Each
mouse was habituated to the testing room for 10 min,
injected IP with saline or baclofen in its home cage, and
commenced testing (test trials) 5 min later. Mice were
tested in each arm in random order, and the latency to
find the platform recorded manually. The latency across
the three test trials was averaged. Three mice (one female
WT, one male WT, one male KO) did not complete the test
on one of the baclofen testing days and were included in
the vehicle, but not baclofen, analysis.
Statistical analysis
Data from each test were approximately normally dis-
tributed (skewness between –1 and 1) with the exception
of open field percentage center time and radial water
maze latency, for which all data were log transformed to
achieve normality. Analyses were conducted in two
stages. First, analyses of genotype and sex differences
were performed in the vehicle condition using factorial
ANOVA. Second, main effects of genotype, sex, and
baclofen dose (within-subject factor) were assessed
across baclofen conditions using repeated-measures
ANOVA. Post hoc comparisons were performed using the
least-significant difference test when significant main ef-
fects or interactions were found. Correlations between
continuous variables were investigated using Pearson’s
correlations. No outliers were removed. All analyses were
performed using Statistica (Dell Inc.; RRID: SCR_014213).
Results
Effects of Fmr1 KO and baclofen on ERP measures
P20
Amplitude of the P20 did not differ between Fmr1 KO
and WT mice (p  0.26; Fig. 1A, C, F) nor between male
and female mice (p  0.45; Fig. 1F) in the vehicle condi-
tion. Baclofen increased P20 amplitude at all doses
[F(3,204)  8.30, p  0.00003; Fig. 1B, D–F], with the
greatest effect at 2.5 mg/kg. Across baclofen doses, P20
amplitude did not differ across genotypes or sexes (p 
0.31 and p  0.98 respectively; Fig. 1F). The effect of
baclofen on P20 amplitude did not differ between Fmr1
KO and WT mice (genotype  drug interaction, p  0.11)
but was larger in female than male mice [sex  drug
interaction, F(3,204)  3.14, p  0.026; Fig. 1F].
N40
A similar pattern was observed with N40 amplitude,
with no significant main effects of genotype or sex with
vehicle (genotype, p  0.86; sex, p  0.51; Fig. 1A, C, G)
or during baclofen treatment (genotype, p  0.11; sex, p
 0.30; Fig. 1B, D, G). There was a significant main effect
of baclofen [F(3,204)  11.75, p  0.000001; Fig. 1E, G].
N40 amplitude was increased at 1 mg/kg (p  0.001) and
2.5 mg/kg (p  0.000002) baclofen relative to vehicle, but
not at 5 mg (p  0.53). The effect of baclofen on N40
amplitude did not differ between Fmr1 KO and WT mice
(genotype  drug interaction, p  0.07) or between fe-
male and male mice (drug  sex interaction, p  0.23).
Effects of Fmr1 KO and baclofen on high-frequency
neural oscillations
Baseline power
The absolute power of gamma (30–80 Hz) frequency
neural oscillations (Fig. 2A, B, E–I), and the relative power
of gamma oscillations [as a proportion of total (0–120 Hz)
power; Fig. 2C, D, J] were quantified, because oscillations
at this frequency are thought to relate to cognitive func-
tion (Salinas and Sejnowski, 2001; Buzsáki and Wang,
2012) as well as being driven by the activity of GABAergic
interneurons (Buzsáki and Wang, 2012) that are impli-
cated in FXS (Adusei et al. 2010; Paluszkiewicz et al.
2011). For baseline absolute gamma power in the vehicle
condition, there was greater power in Fmr1 KO than in WT
mice overall [F(1,68)  11.73, p  0.001; Fig. 2I]. This
genotype difference was present in males (p  0.00002;
Fig. 2I) but not in females (p  0.61) [genotype  sex
interaction: F(1,68)  7.07, p  0.013]. Across all baclofen
doses, the overall genotype difference was still evident
[F(1,68)  11.34, p  0.001]. Again, this genotype differ-
ence trended toward a significant difference in males (p
0.0001; Fig. 2I) but not females [p 0.35; genotype sex
interaction, F(1,68)  3.85, p  0.054]. In the vehicle con-
dition, there was greater baseline absolute gamma power
in females than males [F(1,68) 6.44, p 0.013], driven by
sex differences in WT mice (p  0.00002; Fig. 2I) but not
Fmr1 KO mice (p  0.93) owing to the genotype  sex
interaction. There was no effect of baclofen on baseline
absolute gamma power (p  0.76; Fig. 2I).
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For baseline relative gamma power after vehicle,
there was also greater power in Fmr1 KO mice than in
WT mice [F(1,68)  10.99, p  0.001; Fig. 2J] and a trend
toward a significant genotype sex interaction [F(1,68) 
3.89, p  0.053] with an effect of genotype in males (p
 0.0002; Fig. 2J) but not females (p  0.38). This
genotype effect held across baclofen treatment condi-
tions [F(1,68)  37.06, p  0.000001], and as seen in
vehicle, male Fmr1 KO mice had greater elevations of
relative baseline gamma power compared with WT than
females [genotype  sex interaction, F(1,68)  9.23, p 
0.003; Fig. 2J]. In contrast to absolute gamma power,
there was no overall sex difference (vehicle, p  0.56;
baclofen, p  0.26). Baseline relative gamma power
was strongly decreased by baclofen [F(3,204)  27.21,
p  0.000001; Fig. 2J].
Auditory stimulus–related power
Changes to gamma power in response to auditory stim-
uli were also investigated (Fig. 2K–N). In the vehicle con-
dition, the absolute power of evoked gamma oscillations,
which are time-locked to the stimulus, did not differ be-
tween genotypes (p  0.15; Fig. 2O). However, across all
baclofen treatment groups together, evoked gamma
power was significantly increased in Fmr1 KO mice com-
pared with WT mice [F(1,68)  5.28, p  0.025; Fig. 2O].
There were no sex differences in evoked gamma power
(vehicle, p  0.39; baclofen, p  0.88). A significant
decrease in evoked gamma power was observed after
baclofen [F(3,204)  13.96, p  0.000001; Fig. 2K–N, O],
which was strongest at 5 mg/kg (p 0.000003) relative to
vehicle. A marginal effect was also observed at 2.5 mg/kg
(p 0.054). Baclofen had the same effect in WT and Fmr1
Figure 1. Effects of baclofen on ERPs in Fmr1 KO and WT mice (F-WT, n  16; F-KO, n  15; M-WT, n  23; M-KO, n  18). A–D,
Heat maps and traces showing positive and negative ERP deflections across test trials from representative WT (A, B) and Fmr1 KO
(C, D) mice after vehicle and 2.5 mg/kg baclofen administration. E, Grand average waveforms with characteristic ERP deflections in
all mice (female and male Fmr1 KO and WT) after vehicle or 1, 2.5, and 5 mg/kg baclofen. F, Effects of baclofen on amplitudes of the
P20 component of the ERP in female and male Fmr1 KO and WT mice. G, Effects of baclofen on amplitudes of the N40 ERP
component. F, female, M, male, Veh, vehicle. Error bars represent SEM.
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Figure 2. Effects of baclofen on baseline and auditory stimulus–related gamma oscillations in Fmr1 KO and WT mice (F-WT, n  16;
New Research 6 of 13
January/February 2017, 4(1) e0380-16.2017 eNeuro.org
KO mice (genotype  drug interaction, p  0.17) and
across sexes (sex  drug interaction, p  0.21; Fig. 2O).
The power of induced gamma oscillations, which are not
time-locked to the stimulus, was not influenced by geno-
type (vehicle, p 0.59; baclofen, p 0.35; Fig. 2P) or sex
(vehicle, p  0.69; baclofen, p  0.99). However, induced
gamma power was strongly increased by baclofen at all
doses [F(3,204)  73.59, p  0.000001; Fig. 2P]. This effect
was equivalent in Fmr1 KO and WT mice (genotype 
drug interaction, p 0.81) and female and male mice (sex
 drug interaction, p  0.67).
Effects of Fmr1 KO and baclofen on behavior
There was no difference between Fmr1 KO and WT
mice in the number of beam breaks in 10 min with vehicle
(p  0.33) or during baclofen treatment (p  0.28; Fig. 3A)
in the open-field test. There was also no effect of sex
(vehicle, p 0.67; baclofen, p 0.77). However, baclofen
significantly decreased locomotor activity at all doses
[F(3,213) 39.38, p 0.000001; Fig. 3A] in both genotypes
and sexes (genotype  drug interaction, p  0.52; sex 
drug interaction, p  0.44). For center time in the open
field, there were significant main effects of genotype, sex,
continued
F-KO, n  15; M-WT, n  23; M-KO, n  18). A, B, Baseline absolute power spectra in Fmr1 KO and WT mice (A), and vehicle and
5 mg/kg baclofen treatment conditions (B). C, D, Baseline relative power spectra (normalized to total 0 to 120 Hz power). E–H, Heat
maps showing total power of EEG oscillations at baseline across 2 to 120 Hz frequencies from representative WT (E, F) and Fmr1 KO
(G, H) mice after vehicle and 2.5 mg/kg baclofen administration. Boxes highlight baseline gamma oscillations. I, Baseline absolute
gamma power. J, Baseline relative gamma power. K–N, Heat maps showing evoked power of EEG oscillations after stimulus across
2 to 120 Hz frequencies from representative WT (K, L) and Fmr1 KO (M, N) mice after vehicle and 2.5 mg/kg baclofen administration.
Boxes highlight auditory-evoked gamma oscillations. O, Evoked gamma power. P, Induced gamma power. F, female, M, male, Veh,
vehicle. Error bars represent SEM. p  0.05, p  0.0005, p  0.00005.
Figure 3. Effects of baclofen on behaviors in Fmr1 KO and WT mice. A, Open-field beam breaks in 10 min; F-WT, n  18; F-KO, n
 18; M-WT, n  22; M-KO, n  19. B, Percentage center time spent in the open field. C, Percentage of social interactions in the
three-chamber test; F-WT, n  15; F-KO, n  15; M-WT, n  18; M-KO, n  19. D, Percentage of correct spontaneous alternations
in the continuous T-maze task; F-WT, n  17; F-KO, n  18; M-WT, n  22; M-KO, n  19. E, Average latency to find the platform
during test trials in the modified radial water maze; F-WT, n  18; F-KO, n  18; M-WT, n  18; M-KO, n  18. F, female, M, male,
Veh, vehicle. Error bars represent SEM. p  0.05, p  0.0005.
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and baclofen treatment. Fmr1 KO mice spent a signifi-
cantly greater proportion of the total time in the center
than WT mice [vehicle: F(1,73)  17.70, p  0.00007;
baclofen: F(1,71)  12.49, p  0.0007; Fig. 3B]. Males
spent significantly more time in center than females [ve-
hicle: F(1,73)  7.62, p  0.007; baclofen: F(1,71)  28.68, p
 0.000001; Fig. 3B]. Baclofen significantly decreased
percentage center time [F(3,213)  50.11, p  0.000001;
Fig. 3B], reversing the Fmr1 KO phenotype. This effect
was similar in both genotypes (genotype  drug interac-
tion, p  0.51) but was greater in females [sex  drug
interaction, F(3,213)  3.23, p  0.05; Fig. 3B].
Both Fmr1 KO and WT mice displayed a preference for
interactions with the target mouse rather than the object
(percentage social interactions 50%; Fig. 3C) during the
three-chamber social interaction test. In the vehicle con-
dition, social preference was decreased in Fmr1 KO mice
compared with WT [F(1,63)  4.58, p  0.036; Fig. 3C].
However, during baclofen treatment, this main effect was
not significant (p  0.87). There was no difference be-
tween males and females following either vehicle or
baclofen (vehicle, p  0.59; baclofen, p  0.28). Baclofen
significantly reduced sociability [F(3,168)  10.43, p 
0.000002; Fig. 3C] to a similar extent in both genotypes
(genotype  drug interaction, p  0.11) and sexes (sex 
drug interaction, p  0.70).
Significant main effects of genotype, sex, and treatment
were found on spontaneous alternation in the T-maze.
Fmr1 KO mice had a significantly lower proportion of
correct alternations than WT mice across baclofen doses
[F(1,70)  5.84, p  0.018; Fig. 3D]. This was less evident
in the vehicle condition, which failed to reach significance
(p  0.057). Males made more correct alternations than
females across baclofen doses [F(1,70)  9.16, p  0.003],
but this was not significant in the vehicle condition alone
(p  0.22). The working memory of all mice was signifi-
cantly improved by baclofen [F(3,210)  10.71, p 
0.000001; Fig. 3D], with no significant genotype  drug (p
 0.10) or sex  drug (p  0.84) interactions.
No effects of genotype or sex on latency to find the
platform were observed on the radial water maze during
test trials following vehicle (genotype, p  0.67; sex, p 
0.17). However, across baclofen doses, significant main
effects were found for genotype [F(1,65)  21.70, p 
0.00002; Fig. 3E] and baclofen [F(3,195)  3.55, p  0.015;
Fig. 3E], which were moderated by a genotype  drug
interaction [F(3,195)  3.56, p  0.015]. The main effect of
genotype arose because there were contrasting effects of
baclofen in WT and Fmr1 KO mice (Fig. 3E). In WT mice,
baclofen at all doses decreased latency compared with
vehicle (all at least p  0.05), whereas in Fmr1 KO mice,
baclofen had no significant effect. Finally, across baclofen
doses, latency to approach the platform was lower in
female mice than male mice [F(1,65)  8.64, p  0.005].
Relationship between baclofen gamma response
and T-maze performance improvement
To explore the plausibility of using EEG to predict be-
havioral treatment responsiveness, we investigated
whether rescue of specific EEG abnormalities (baseline
relative gamma power and evoked gamma power) at an
individual level was associated with improvement in
T-maze spontaneous alternation or open-field center time
in Fmr1 KO and WT mice. These parameters were inves-
tigated at 2.5 mg/kg baclofen, the dose at which most
consistent improvement of electrophysiological and be-
havioral deficits in Fmr1 KO mice was seen.
First, mice were grouped into baseline-relative gamma
responders, whose baseline relative gamma power de-
creased with baclofen (in Fmr1 KO mice, this represented
rescue of their abnormal baseline relative gamma power),
and baseline relative gamma nonresponders, whose
baseline relative gamma power increased with baclofen.
There was no difference in  T-maze performance (the
change in percentage correct alternations after 2.5 mg/kg
baclofen treatment compared with vehicle) between
baseline relative gamma responders and nonresponders
(all mice, p  0.79; WT only, p  0.26; Fmr1 KO only, p 
0.51; Fig. 4A–C). There was also no correlation of 
baseline relative gamma power with  T-maze perfor-
mance in WT or Fmr1 KO mice (WT only, p  0.77; Fmr1
KO only, p  0.50; Fig. 4D, E]. Second, mice were
grouped into evoked gamma responders, whose evoked
gamma power decreased with baclofen (in Fmr1 KOmice,
this represented rescue of their deficit), and evoked
gamma nonresponders, whose evoked gamma power
increased with baclofen. In contrast to baseline gamma,
there was a significant difference in postbaclofen T-maze
performance between evoked gamma responders and
nonresponders (Fig. 4F–H). These effects reached signif-
icance in all mice together (t  3.16, df  66, p  0.003;
Fig. 4F) and in WT mice (t  3.40, df  33, p  0.002; Fig.
4G), but failed to do so in Fmr1 KOmice (t 1.35, df 31,
p  0.19; Fig. 4H).There was an inverse correlation be-
tween  evoked gamma power responses and  T-maze
performance in all mice (r  –0.33, p  0.006) and in WT
mice (r  –0.43, p  0.010; Fig. 4I) but not in Fmr1 KO
mice (r  –0.26, p  0.14; Fig. 4J). Collectively, the
animals that displayed the greatest baclofen-induced de-
crease in evoked gamma power showed the greatest
improvement in T-maze performance. None of the above
relationships were evident for open-field center time, in
that there were no relationships between changes in
baseline relative gamma power or evoked gamma power
and open-field center time after 2.5 mg/kg baclofen (data
not shown). Similarly, there were no significant correla-
tions between changes in induced power and behavior
after 2.5 mg/kg baclofen, or between changes in EEG
measures and sociability (data not shown).
Discussion
After mixed results in human and animal studies, it is
unclear whether baclofen and other pharmacotherapies
targeting GABAergic neurotransmission can effectively
treat the symptoms of FXS, particularly in the absence of
biomarker-based strategies to target treatment to subsets
of individuals. In this study, we present evidence that (a)
sensory hypersensitivity occurs in Fmr1 KO mice, as in-
dexed by increased evoked EEG gamma power, (b)
baclofen normalizes this increased evoked EEG gamma
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power and improves working memory (T-maze perfor-
mance), and (c) at an individual level, normalization of
evoked gamma oscillations was associated with improve-
ment in working memory. Our study also suggests that
some Fmr1 KO–related deficits, such as impaired socia-
bility and episodic memory (radial water maze perfor-
mance), may be impervious to rescue by baclofen.
Overall, these findings indicate that racemic baclofen may
have benefit for remediating sensory hypersensitivity and
some cognitive deficits in FXS and suggest that evoked
gamma oscillations may have potential utility for predic-
tion of treatment responsiveness in some behavioral do-
mains in the condition.
Increased evoked gamma power in Fmr1 KO mice is
consistent with sensory hypersensitivity (Karaka and
Baar, 1998), which is also seen in Fmr1 KO mice in the
form of diminished ERP N1 habituation (Lovelace et al.
2016), neuronal hyperexcitability in the auditory cortex
(Rotschafer and Razak, 2014), and increased prepulse
inhibition (Chen and Toth, 2001). Increased sensitivity to
sensory stimuli is also often observed in individuals with
FXS (Kogan et al. 2004; Baranek et al. 2008). The dimi-
nution of evoked gamma power by racemic baclofen
suggests that this agent may be particularly valuable in
targeting the specific sensory hypersensitivity endophe-
notype in FXS.
A key finding of this study was that changes in evoked
gamma power after 2.5 mg/kg baclofen were related to
changes in T-maze performance, such that evoked
gamma responders showed greater T-maze performance
improvement than nonresponders. Baclofen-induced
EEG changes, rather than predrug EEG measures, were
analyzed because of their greater clinical potential. They
enable a within-subject absolute criterion (evoked gamma
decrease, yes/no) to be used to classify individual sub-
jects and do not require normative reference data. In
contrast, use of predrug evoked gamma power (analo-
gous to vehicle treatment) would involve determination of
Figure 4. Relationships between changes in gamma power and improvements in T-maze performance after 2.5 mg/kg baclofen. A–C,
Differences in T-maze performance between baseline relative gamma responders and baseline relative gamma nonresponders. D, E,
Correlation of changes in relative baseline gamma power after 2.5 mg/kg baclofen with changes in T-maze performance in WT and
Fmr1 KO mice. F–H, Differences in T-maze performance between evoked gamma responders and evoked gamma nonresponders.
I, J, Correlation of changes in evoked gamma power after 2.5 mg/kg baclofen with changes in T-maze performance in WT mice and
Fmr1 KO mice. BAC, baclofen, N.S., not significant. Error bars represent SEM. p  0.005.
New Research 9 of 13
January/February 2017, 4(1) e0380-16.2017 eNeuro.org
normative ranges and collection of extensive reference
data. Between genotype groups, there was a less strong
relationship between baclofen-induced changes in
evoked gamma oscillations and T maze performance in
Fmr1 KO mice than in WT mice. This was expected, since
baclofen targets a neurotransmitter system known to be
dysregulated in Fmr1 KO mice. However, our findings
suggest that further preclinical study of the possible link
between evoked power changes and drug effectiveness
for other pharmacotherapies is warranted given the po-
tential benefit of this approach for individuals with FXS.
Increased baseline gamma power in FXS is a robust
feature of the disorder, indicative of increased network
noise and network hyperexcitability (Gandal et al. 2012a).
It is observed in humans with FXS (Ethridge et al. 2016)
and ASD (Orekhova et al. 2007; Wang et al. 2013). It is
also seen in Fmr1 KO mice in vivo (in this study) and in
vitro in thalamocortical slices from Fmr1 KO mice (Gibson
et al. 2008). Racemic baclofen did not alter absolute
power of baseline gamma oscillations in our study, in
contrast to a prior study in which L-baclofen decreased
absolute power of oscillations between 21 and 50 Hz
(Marrosu et al. 2006). However, baclofen did decrease the
relative power of baseline gamma oscillations as a pro-
portion of total oscillatory activity. Further work is required
to determine whether the importance of high-frequency
oscillations lies in their absolute power or their power
relative to other oscillatory activity. If absolute gamma
power is more neurobiologically relevant, the failure of
baclofen to rescue increased absolute baseline gamma
power in Fmr1 KO mice may represent a limitation of this
pharmacotherapy. If relative power of baseline oscilla-
tions has particular relevance, then investigation of other
frequencies in Fmr1 KO mice is warranted, given that
differences in relative upper alpha (10–12 Hz) and theta
(4–8 Hz) power have been described in FXS (Van der
Molen and Van der Molen, 2013). Nonetheless, as a po-
tential translational biomarker, baseline gamma power
may be a useful tool for designing and evaluating future
therapeutic strategies for FXS.
The behavioral effects of baclofen reported here are
partially consistent with prior studies. Improvement of
spatial working memory by systemic baclofen has previ-
ously been reported in a similar T-maze task (Gandal et al.
2012b) and is in line with other cognition-enhancing prop-
erties of baclofen, including increased behavioral flexibil-
ity in rats (Beas et al. 2016). Because loss of FMRP results
in abnormally increased open-field center exploration, it
has been argued that the decrease in open-field center
time by baclofen represents a beneficial, anxiety-
normalizing effect (Bhogal and Jongens, 2010). Interest-
ingly, this effect was not seen with arbaclofen at 1.5
mg/kg (Qin et al. 2015). Together with these beneficial
effects of baclofen, there were indications of other effects
that may not be therapeutically helpful. In particular,
baclofen decreased sociability at all doses. This contrasts
with two previous studies, one that found a beneficial
effect of baclofen on sociability (Gandal et al. 2012b) and
another that found no effect, but reported an increase in
preference for social novelty (preference for novel over
familiar stimulus mouse; Qin et al. 2015).
Although Fmr1 KO mice effectively mimic the loss of
FMRP protein in FXS, they do not display a highly con-
sistent behavioral phenotype. Some studies have re-
ported spatial memory deficits in Fmr1 KO mice (Bakker
et al. 1994; D’Hooge et al. 1997), but others have not
(Peier et al. 2000; Leach et al. 2016). Deficits in working
and episodic memory in Fmr1 KO mice are consistent
with the clinical picture in FXS, in which intellectual dis-
ability is commonly seen. Decreased anxiety-like behavior
and hyperactivity in the open field in Fmr1 KO mice are
very often observed (e.g., Uutela et al. 2012; Dolan et al.
2013; Ding et al. 2014) but not always (Veeraragavan et al.
2011). A possible reason for this discrepancy is that the
hyperactivity phenotype may diminish with repeated test-
ing (Kramvis et al. 2013). Decreased social interactions by
Fmr1 KOmice have been reported in free-interacting tests
(Hébert et al. 2014; Oddi et al. 2015). However, when the
three-chamber social interaction test is used, abnormali-
ties are often not seen in sociability (Liu et al. 2011; Hébert
et al. 2014), although other work has even shown in-
creased sociability in Fmr1 KO mice (Gantois et al. 2013).
A possible reason for this inconsistency across studies
with Fmr1 KO mice could involve stress, since Fmr1 KO
mice appear to show enhanced corticosterone secretion
in response to acute stress (Markham et al. 2006; Ghilan
et al. 2015, but see Qin and Smith, 2008). The differential
effects of acute stress on Fmr1 KO compared with con-
trols may contribute to the Fmr1 KO behavioral phenotype
in some tests, such as the T-maze or radial arm maze.
Consequently, this phenotype may be particularly im-
pacted by differences in the testing environment between
studies. Furthermore, the animals in this study were indi-
vidually housed after surgery and are likely to have expe-
rienced some longer-term stress associated with
sustained social isolation that was not experienced by
animals in other studies. Heightened adaptive or mal-
adaptive responses of Fmr1 KO mice to chronic stress
(Qin et al. 2011) may have further influenced genotype
effects in this study. Future studies are warranted to
clarify the role of stress in Fmr1-related pathology in mice
and determine whether social isolation or socialization
impacts the expression of functional deficits in humans
with FXS.
Sex  genotype interactions were observed for abso-
lute and relative baseline gamma power, with increased
baseline gamma power seen in male but not female Fmr1
KO mice. This is consistent with the increased severity of
FXS in human males (Crawford et al. 2001). However,
unlike in humans, sex differences in the expression of
FXS-related phenotypes in this study are unlikely to relate
to variable penetrance of the genetic manipulation/muta-
tion, since this study used complete knockout of Fmr1 for
both sexes. Instead, they are more likely to reflect the
interaction of FMRP signaling with sex differences in other
pathways.
Several lines of evidence have identified GABAergic
interneurons as the primary source of gamma oscillations
in the brain (Traub et al. 1996; Bartos et al. 2007). Mice
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with the NMDA subunit 1 receptor selectively removed
from parvalbumin-expressing GABAergic interneurons
show a similar EEG profile to Fmr1 KO mice, including
increased basal gamma EEG, and display several autism-
like behavioral changes (Carlén et al. 2012; Saunders
et al. 2013; Billingslea et al. 2014). Increased gamma
oscillations are thought to be due to a loss of the normal
inhibitory control typically exerted by GABAergic cells,
leading toward a loss of excitatory/inhibitory balance. This
suggests that the primary pathology underlying the EEG
abnormalities reported here in Fmr1 KO mice may reflect
a loss of GABA integrity. Baclofen stimulates GABA-B
receptors both presynaptically, resulting in decreased
glutamate release (Isaacson and Hille, 1997), and post-
synaptically, resulting in decreased excitability due to
voltage gated potassium channel activation (Lüscher et al.
1997). GABA-B agonism by baclofen may compensate for
GABAergic pathology in Fmr1 KO mice, such as de-
creased GABA receptor abundance (Gantois et al. 2006;
Adusei et al. 2010). Additionally, arbaclofen has also been
shown to decrease protein synthesis (Henderson et al.
2012; Qin et al. 2015), potentially counteracting excess
protein production due to FMRP loss (Darnell et al. 2011).
This study had a number of limitations. A within-subject
design was used, enabling assessment of the acute ef-
fects of baclofen across multiple domains. However, later
behavioral tests (such as social interaction and radial
water maze) may have been influenced by lingering ef-
fects of prior baclofen exposure despite the 4 to 5 d
washout. In the open-field test and other tests, habitua-
tion to the test environment may also have modified the
behavioral measures and confounded the effects of
baclofen. Furthermore, findings at the highest baclofen
dose (5 mg/kg) may have been influenced by the sedative
effect of the drug, accounting for its diminished efficacy in
T-maze and water maze tests at that dose. Ultimately, the
value of the findings described in this study will be deter-
mined by the extent of their translatability and predictive
validity for individuals with FXS.
References
Adusei DC, Pacey LK, Chen D, Hampson DR (2010) Early develop-
mental alterations in GABAergic protein expression in fragile X
knockout mice. Neuropharmacology 59:167–171. CrossRef Med-
line
Bailey DB, Raspa M, Olmsted M, Holiday DB (2008) Co-occurring
conditions associated with FMR1 gene variations: findings from a
national parent survey. Am J Med Genet Part A 146:2060–2069.
CrossRef
Bailey DB, Jr., Raspa M, Bishop E, Olmsted M, Mallya UG, Berry-
Kravis E (2012) Medication utilization for targeted symptoms in
children and adults with fragile X syndrome: US survey. J Dev
Behav Pediatr 33:62–69. CrossRef Medline
Bakker CE, Verheij C, Willemsen R, Vanderhelm R, Oerlemans F,
Vermey M, Bygrave A, Hoogeveen AT, Oostra BA, Reyniers E,
Deboulle K, Dhooge R, Cras P, Vanvelzen D, Nagels G, Martin JJ,
Dedeyn PP, Darby JK, Willems PJ (1994) Fmr1 knockout mice: a
model to study fragile X mental retardation. Cell 78:23–33.
Baranek GT, Roberts JE, David FJ, Sideris J, Mirrett PL, Hatton DD,
Bailey DB Jr. (2008) Developmental trajectories and correlates of
sensory processing in young boys with fragile X syndrome. Phys
Occup Ther Pediatr 28:79–98. Medline
Bartos M, Vida I, Jonas P (2007) Synaptic mechanisms of synchro-
nized gamma oscillations in inhibitory interneuron networks. Nat
Rev Neurosci 8:45–56. CrossRef Medline
Beas BS, Setlow B, Bizon JL (2016) Effects of acute administration of
the GABA(B) receptor agonist baclofen on behavioral flexibility in
rats. Psychopharmacology (Berl) 233:2787–2797. CrossRef Med-
line
Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M,
Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang
PP, Carpenter RL, Bear MF, Hagerman RJ (2012) Effects of
STX209 (arbaclofen) on neurobehavioral function in children and
adults with fragile X syndrome: a randomized, controlled, phase 2
trial. Sci Transl Med 4:152ra127. CrossRef Medline
Bhogal B, Jongens TA (2010) Fragile X syndrome and model organ-
isms: identifying potential routes of therapeutic intervention. Dis
Model Mech 3:693–700. CrossRef Medline
Billingslea EN, Tatard-Leitman VM, Anguiano J, Jutzeler CR, Suh J,
Saunders JA, Morita S, Featherstone RE, Ortinski PI, Gandal MJ,
Lin R, Liang Y, Gur RE, Carlson GC, Hahn CG, Siegel SJ (2014)
Parvalbumin cell ablation of NMDA-R1 causes increased resting
network excitability with associated social and self-care deficits.
Neuropsychopharmacology 39:1603–1613. CrossRef Medline
Buzsáki G, Wang XJ (2012) Mechanisms of gamma oscillations.
Annu Rev Neurosci 35:203–225. CrossRef Medline
Carlén M, Meletis K, Siegle JH, Cardin JA, Futai K, Vierling-Claassen
D, Rühlmann C, Jones SR, Deisseroth K, Sheng M, Moore CI, Tsai
LH (2012) A critical role for NMDA receptors in parvalbumin in-
terneurons for gamma rhythm induction and behavior. Mol Psy-
chiatry 17:537–548. CrossRef Medline
Castrén M, Pääkkönen A, Tarkka IM, Ryynänen M, Partanen J (2003)
Augmentation of auditory N1 in children with fragile X syndrome.
Brain Topogr 15:165–171. Medline
Chen L, Toth M (2001) Fragile X mice develop sensory hyperreactivity
to auditory stimuli. Neuroscience 103:1043–1050. Medline
Crawford DC, Acuña JM, Sherman SL (2001) FMR1 and the fragile X
syndrome: human genome epidemiology review. Genet Med
3:359–371. CrossRef Medline
D’Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K,
Kooy RF, Oostra BA, Willems PJ, DeDeyn PP (1997) Mildly im-
paired water maze performance in male Fmr1 knockout mice.
Neuroscience 76:367–376. Medline
Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE,
Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD,
Darnell RB (2011) FMRP stalls ribosomal translocation on mRNAs
linked to synaptic function and autism. Cell 146:247–261. Cross-
Ref Medline
Delorme A, Makeig S (2004) EEGLAB: an open source toolbox for
analysis of single-trial EEG dynamics including independent com-
ponent analysis. J Neurosci Methods 134:9–21. CrossRef Medline
Ding Q, Sethna F, Wang H (2014) Behavioral analysis of male and
female Fmr1 knockout mice on C57BL/6 background. Behav Brain
Res 271:72–78. CrossRef Medline
Dolan BM, Duron SG, Campbell DA, Vollrath B, Shankaranarayana
Rao BS, Ko HY, Lin GG, Govindarajan A, Choi SY, Tonegawa S
(2013) Rescue of fragile X syndrome phenotypes in Fmr1 KO mice
by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci
U S A 110:5671–5676. CrossRef Medline
Ehrlichman RS, Luminais SN, White SL, Rudnick ND, Ma N, Dow HC,
Kreibich AS, Abel T, Brodkin ES, Hahn CG, Siegel SJ (2009)
Neuregulin 1 transgenic mice display reduced mismatch negativ-
ity, contextual fear conditioning and social interactions. Brain Res
1294:116–127. CrossRef Medline
Ethridge LE, White SP, Mosconi MW, Wang J, Byerly MJ, Sweeney
JA (2016) Reduced habituation of auditory evoked potentials indi-
cate cortical hyper-excitability in fragile X syndrome. Transl Psy-
chiatr 6:e787. CrossRef Medline
Featherstone RE, Shin R, Kogan JH, Liang YL, Matsumoto M, Siegel
SJ (2015) Mice with subtle reduction of NMDA NR1 receptor
subunit expression have a selective decrease in mismatch nega-
New Research 11 of 13
January/February 2017, 4(1) e0380-16.2017 eNeuro.org
tivity: implications for schizophrenia prodromal population. Neu-
robiol Dis 73:289–295. CrossRef
Frankland PW, Wang Y, Rosner B, Shimizu T, Balleine BW, Dykens
EM, Ornitz EM, Silva AJ (2004) Sensorimotor gating abnormalities
in young males with fragile X syndrome and Fmr1-knockout mice.
Mol Psychiatry 9:417–425. CrossRef Medline
Gandal MJ, Edgar JC, Klook K, Siegel SJ (2012a) Gamma synchrony:
towards a translational biomarker for the treatment-resistant
symptoms of schizophrenia. Neuropharmacology 62:1504–1518.
Gandal MJ, Sisti J, Klook K, Ortinski PI, Leitman V, Liang Y, Thieu T,
Anderson R, Pierce RC, Jonak G, Gur RE, Carlson G, Siegel SJ
(2012b) GABAB-mediated rescue of altered excitatory-inhibitory
balance, gamma synchrony and behavioral deficits following con-
stitutive NMDAR-hypofunction. Transl Psychiatry 2:e142.
Gantois I, Vandesompele J, Speleman F, Reyniers E, D’Hooge R,
Severijnen LA, Willemsen R, Tassone F, Kooy RF (2006) Expres-
sion profiling suggests underexpression of the GABA(A) receptor
subunit delta in the fragile X knockout mouse model. Neurobiol Dis
21:346–357. CrossRef Medline
Gantois I, Pop AS, de Esch CE, Buijsen RA, Pooters T, Gomez-
Mancilla B, Gasparini F, Oostra BA, D’Hooge R, Willemsen R
(2013) Chronic administration of AFQ056/Mavoglurant restores
social behaviour in Fmr1 knockout mice. Behav Brain Res 239:72–
79. CrossRef Medline
Ghilan M, Hryciw BN, Brocardo PS, Bostrom CA, Gil-Mohapel J,
Christie BR (2015) Enhanced corticosteroid signaling alters syn-
aptic plasticity in the dentate gyrus in mice lacking the fragile X
mental retardation protein. Neurobiol Dis 77:26–34. CrossRef
Medline
Gibson JR, Bartley AF, Hays SA, Huber KM (2008) Imbalance of
neocortical excitation and inhibition and altered UP states reflect
network hyperexcitability in the mouse model of fragile X syn-
drome. J Neurophysiol 100:2615–2626. CrossRef Medline
Gonçalves JT, Anstey JE, Golshani P, Portera-Cailliau C (2013)
Circuit level defects in the developing neocortex of Fragile X mice.
Nat Neurosci 16:903–909. CrossRef Medline
Healy A, Rush R, Ocain T (2011) Fragile X syndrome: an update on
developing treatment modalities. ACS Chem Neurosci 2:402–410.
CrossRef Medline
Hébert B, Pietropaolo S, Même S, Laudier B, Laugeray A, Doisne N,
Quartier A, Lefeuvre S, Got L, Cahard D, Laumonnier F, Crusio WE,
Pichon J, Menuet A, Perche O, Briault S (2014) Rescue of fragile X
syndrome phenotypes in Fmr1 KO mice by a BKCa channel
opener molecule. Orphanet J Rare Dis 9:124. CrossRef Medline
Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond
RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren
ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM
(2012) Reversal of disease-related pathologies in the fragile X
mouse model by selective activation of GABAB receptors with
arbaclofen. Sci Transl Med 4:152ra128. CrossRef Medline
Isaacson JS, Hille B (1997) GABA(B)-mediated presynaptic inhibition
of excitatory transmission and synaptic vesicle dynamics in cul-
tured hippocampal neurons. Neuron 18:143–152. Medline
Karaka S, Baar E (1998) Early gamma response is sensory in
origin: a conclusion based on cross-comparison of results from
multiple experimental paradigms. Int J Psychophysiol 31:13–31.
CrossRef
Kogan CS, Bertone A, Cornish K, Boutet I, Der Kaloustian VM,
Andermann E, Faubert J, Chaudhuri A (2004) Integrative cortical
dysfunction and pervasive motion perception deficit in fragile X
syndrome. Neurology 63:1634–1639. Medline
Kramvis I, Mansvelder HD, Loos M, Meredith R (2013) Hyperactivity,
perseveration and increased responding during attentional rule
acquisition in the fragile X mouse model. Front Behav Neurosci
7:172. CrossRef Medline
Leach PT, Hayes J, Pride M, Silverman JL, Crawley JN (2016) Normal
performance of Fmr1 mice on a touchscreen delayed nonmatching
to position working memory task. eNeuro 3:ENEURO.0143–
15.2016. CrossRef
Liu ZH, Chuang DM, Smith CB (2011) Lithium ameliorates pheno-
typic deficits in a mouse model of fragile X syndrome. Int J
Neuropsychopharmacol 14:618–630. CrossRef
Lovelace JW, Wen TH, Reinhard S, Hsu MS, Sidhu H, Ethell IM,
Binder DK, Razak KA (2016) Matrix metalloproteinase-9 deletion
rescues auditory evoked potential habituation deficit in a mouse
model of fragile X syndrome. Neurobiol Dis 89:126–135. CrossRef
Lozano R, Hare EB, Hagerman RJ (2014) Modulation of the GABAe-
rgic pathway for the treatment of fragile X syndrome. Neuropsy-
chiatr Dis Treat 10:1769–1779. CrossRef Medline
Lüscher C, Jan LY, Stoffel M, Malenka RC, Nicoll RA (1997) G
protein-coupled inwardly rectifying K channels (GIRKs) mediate
postsynaptic but not presynaptic transmitter actions in hippocam-
pal neurons. Neuron 19:687–695. CrossRef
Markham JA, Beckel-Mitchener AC, Estrada CM, Greenough WT
(2006) Corticosterone response to acute stress in a mouse model
of fragile X syndrome. Psychoneuroendocrinology 31:781–785.
CrossRef Medline
Marrosu F, Santoni F, Fa M, Puligheddu M, Barberini L, Genugu F,
Frau R, Manunta M, Mereu G (2006) Beta and gamma range EEG
power-spectrum correlation with spiking discharges in DBA/2J
mice absence model: role of GABA receptors. Epilepsia 47:489–
494. CrossRef Medline
Oddi D, Subashi E, Middei S, Bellocchio L, Lemaire-Mayo V,
Guzmán M, Crusio WE, D’Amato FR, Pietropaolo S (2015) Early
social enrichment rescues adult behavioral and brain abnormali-
ties in a mouse model of fragile X syndrome. Neuropsychophar-
macology 40:1113–1122. CrossRef
Orekhova EV, Stroganova TA, Nygren G, Tsetlin MM, Posikera IN,
Gillberg C, Elam M (2007) Excess of high frequency electroen-
cephalogram oscillations in boys with autism. Biol Psychiatr 62:
1022–1029. CrossRef Medline
Pacey LK, Heximer SP, Hampson DR (2009) Increased GABA(B)
receptor-mediated signaling reduces the susceptibility of fragile X
knockout mice to audiogenic seizures. Mol Pharmacol 76:18–24.
CrossRef Medline
Paluszkiewicz SM, Olmos-Serrano JL, Corbin JG, Huntsman MM
(2011) Impaired inhibitory control of cortical synchronization in
fragile X syndrome. J Neurophysiol 106:2264–2272. CrossRef
Medline
Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL
(2000) (Over)correction of FMR1 deficiency with YAC transgenics:
behavioral and physical features. Hum Mol Genet 9:1145–1159.
Medline
Qin M, Smith CB (2008) Unaltered hormonal response to stress in a
mouse model of fragile X syndrome. Psychoneuroendocrinology
33:883–889. CrossRef Medline
Qin M, Xia Z, Huang T, Smith CB (2011) Effects of chronic immobi-
lization stress on anxiety-like behavior and basolateral amygdala
morphology in Fmr1 knockout mice. Neuroscience 194:282–290.
CrossRef Medline
Qin M, Huang T, Kader M, Krych L, Xia Z, Burlin T, Zeidler Z, Zhao T,
Smith CB (2015) R-baclofen reverses a social behavior deficit and
elevated protein synthesis in a mouse model of fragile X syndrome.
Int J Neuropsychopharmacol 18:pii:pyv034. CrossRef
Radwan B, Dvorak D, Fenton AA (2016) Impaired cognitive discrim-
ination and discoordination of coupled theta-gamma oscillations in
Fmr1 knockout mice. Neurobiol Dis 88:125–138. CrossRef Medline
Rotschafer SE, Razak KA (2014) Auditory processing in fragile X
syndrome. Front Cell Neurosci 8:19. CrossRef Medline
Salinas E, Sejnowski TJ (2001) Correlated neuronal activity and the
flow of neural information. Nat Rev Neurosci 2:539–550. CrossRef
Medline
Sankoorikal GM, Kaercher KA, Boon CJ, Lee JK, Brodkin ES (2006)
A mouse model system for genetic analysis of sociability:
C57BL/6J versus BALB/cJ inbred mouse strains. Biol Psychiatry
59:415–423. CrossRef Medline
Saunders JA, Tatard-Leitman VM, Suh J, Billingslea EN, Roberts TP,
Siegel SJ (2013) Knockout of NMDA receptors in parvalbumin
New Research 12 of 13
January/February 2017, 4(1) e0380-16.2017 eNeuro.org
interneurons recreates autism-like phenotypes. Autism Res 6:69–
77. CrossRef Medline
Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM,
Baker S, Crawley JN (2015) GABAB receptor agonist R-baclofen
reverses social deficits and reduces repetitive behavior in two
mouse models of autism. Neuropsychopharmacology 40:2228–
2239. CrossRef Medline
Sinclair D, Oranje B, Razak KA, Siegel SJ, Schmid S (2016) Sensory
processing in autism spectrum disorders and fragile X syndrome:
from the clinic to animal models. Neurosci Biobehav Rev pii:
S0149-7634(15)30318-3.
St Clair DM, Blackwood DH, Oliver CJ, Dickens P (1987) P3 abnor-
mality in fragile X syndrome. Biol Psychiatry 22:303–312. Medline
Tatard-Leitman VM, Jutzeler CR, Suh J, Saunders JA, Billingslea EN,
Morita S, White R, Featherstone RE, Ray R, Ortinski PI, Banerjee A,
Gandal MJ, Lin R, Alexandrescu A, Liang Y, Gur RE, Borgmann-
Winter KE, Carlson GC, Hahn C-G, Siegel SJ (2015) Pyramidal cell
selective ablation of N-methyl-D-aspartate receptor 1 causes in-
crease in cellular and network excitability. Biol Psychiatr 77:556–
568. CrossRef Medline
Traub RD, Whittington MA, Colling SB, Buzsáki G, Jefferys JG (1996)
Analysis of gamma rhythms in the rat hippocampus in vitro and in
vivo. J Physiol 493(Pt 2):471–484. CrossRef
Turner G, Webb T, Wake S, Robinson H (1996) Prevalence of fragile
X syndrome. Am J Med Genet 64:196–197. CrossRef Medline
Uutela M, Lindholm J, Louhivuori V, Wei H, Louhivuori LM, Per-
tovaara A, Akerman K, Castrén E, Castrén ML (2012) Reduction of
BDNF expression in Fmr1 knockout mice worsens cognitive defi-
cits but improves hyperactivity and sensorimotor deficits. Gen
Brain Behav 11:513–523. CrossRef Medline
Van der Molen MJ, Van der Molen MW (2013) Reduced alpha and
exaggerated theta power during the resting-state EEG in fragile X
syndrome. Biol Psychol 92:216–219. CrossRef Medline
Van der Molen MJ, Van der Molen MW, Ridderinkhof KR, Hamel BC,
Curfs LM, Ramakers GJ (2012a) Auditory change detection in
fragile X syndrome males: a brain potential study. Clin Neuro-
physiol 123:1309–1318.
Van der Molen MJ, Van der Molen MW, Ridderinkhof KR, Hamel BC,
Curfs LM, Ramakers GJ (2012b) Auditory and visual cortical ac-
tivity during selective attention in fragile X syndrome: a cascade of
processing deficiencies. Clin Neurophysiol 123:720–729.
Veeraragavan S, Bui N, Perkins JR, Yuva-Paylor LA, Carpenter RL,
Paylor R (2011) Modulation of behavioral phenotypes by a mus-
carinic M1 antagonist in a mouse model of fragile X syndrome.
Psychopharmacology 217:143–151. CrossRef
Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner
O, Richards S, Victoria MF, Zhang FP, et al. (1991) Identification of
a gene (FMR-1) containing a CGG repeat coincident with a break-
point cluster region exhibiting length variation in fragile X syn-
drome. Cell 65:905–914. Medline
Wang J, Barstein J, Ethridge LE, Mosconi MW, Takarae Y, Sweeney
JA (2013) Resting state EEG abnormalities in autism spectrum
disorders. J Neurodev Disord 5:24. CrossRef Medline
New Research 13 of 13
January/February 2017, 4(1) e0380-16.2017 eNeuro.org
